SREBF2 and cancer: Taken together, our data suggest that loss-of-function Fbw7 mutations in cancer cells could result in the stabilization of pre-existing nuclear SREBP1 molecules, enhanced expression of SREBP target genes and the accumulation of intracellular lipids, thereby triggering the feedback mechanism controlling the activation of SREBP2.